<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13D</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0002109116</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, $0.0001 par value</securitiesClassTitle>
      <dateOfEvent>03/31/2026</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001855485</issuerCIK>
        <issuerCusips>
          <issuerCusipNumber>320703408</issuerCusipNumber>
        </issuerCusips>
        <issuerName>Calidi Biotherapeutics, Inc.</issuerName>
        <address>
          <com:street1>4475 EXECUTIVE DRIVE</com:street1>
          <com:street2>SUITE 200</com:street2>
          <com:city>SAN DIEGO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92121</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Chellsea Noelle Cartoscelli</personName>
          <personPhoneNum>9165040529</personPhoneNum>
          <personAddress>
            <com:street1>2315 Capitol Avenue</com:street1>
            <com:city>Sacramento</com:city>
            <com:stateOrCountry>CA</com:stateOrCountry>
            <com:zipCode>95816</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0002109116</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Gavrilov Ognian Anguelov</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>20000.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>20000.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>20000.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>0.3</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, $0.0001 par value</securityTitle>
        <issuerName>Calidi Biotherapeutics, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>4475 EXECUTIVE DRIVE</com:street1>
          <com:street2>SUITE 200</com:street2>
          <com:city>SAN DIEGO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92121</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item2>
        <filingPersonName>Ognian Anguelov Gavrilov</filingPersonName>
        <principalBusinessAddress>2315 Capitol Avenue, Sacramento, CA 95816</principalBusinessAddress>
        <principalJob>Managing Partner, Gavrlilov &amp; Brooks, 2315 Capitol Avenue, Sacramento, CA 95816</principalJob>
        <hasBeenConvicted>No.</hasBeenConvicted>
        <convictionDescription>No.</convictionDescription>
        <citizenship>United States of America </citizenship>
      </item2>
      <item3>
        <fundsSource>Not Applicable. This Schedule 13D relates to the disposition of securities by the Reporting Person. </fundsSource>
      </item3>
      <item4>
        <transactionPurpose>The Reporting Person has effected dispositions of Shares as described in Item 5, resulting in beneficial ownership of approximately 0.3% of the outstanding Shares. The Reporting Person does not currently have any plans or proposals that relate to or would result in any of the actions described in Item 4 of Schedule 13D. However, the Reporting Person may, from time to time, acquire or dispose of securities of the Issuer in the open market or otherwise, depending on market conditions and other factors. </transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>20,000.00</percentageOfClassSecurities>
        <numberOfShares>0</numberOfShares>
        <transactionDesc>20,000.00</transactionDesc>
        <listOfShareholders>0</listOfShareholders>
        <date5PercentOwnership>March 31, 2026</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>Not Applicable</contractDescription>
      </item6>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Gavrilov Ognian Anguelov</signatureReportingPerson>
        <signatureDetails>
          <signature>Ognian Anguelov Gavrilov</signature>
          <title>Ognian Anguelov Gavrilov, Managing Partner</title>
          <date>03/31/2026</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
